Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07455253
Active, not recruiting Observational

Effectiveness and Cost-effectiveness of VTE Prevention Strategies in Gynecological Surgery

NCT07455253 · tracked via the Priya Life Science China tracker
Sponsor
Affiliated Hospital of Nantong University
Phase
Observational
Started
2025-11-10
Last updated
2026-03-06

Condition(s) studied

Venous ThromboembolismDeep Vein Thrombosis (DVT)Pulmonary Embolism (PE)Gynecological Surgery

Study summary

Venous thromboembolism (VTE) is a highly preventable but potentially fatal complication following gynecological surgery. The Caprini risk assessment model is widely used, but real-world evidence evaluating the net clinical benefit and cost-effectiveness of different prophylaxis strategies (mechanical vs. pharmacological) in gynecological patients with Caprini score $\\ge$ 2 is still lacking. This study aims to evaluate the relative effectiveness of basic, mechanical, and pharmacological VTE prophylaxis strategies using a retrospective 1:3 matched nested case-control design. Furthermore, a decision tree model will be constructed to evaluate the incremental cost-effectiveness ratio (ICER) of these strategies to provide health economic evidence for optimizing VTE management pathways in gynecology

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Female patients aged $\\ge$ 18 years. Underwent inpatient gynecological surgery (benign or malignant indications). Postoperative Caprini risk score $\\ge$ 2. Complete medical and billing records available in the hospital information system. Exclusion Criteria: * Diagnosis of VTE prior to the current surgery. Currently receiving therapeutic anticoagulation for other medical conditions (e.g., atrial fibrillation, mechanical heart valves). Inferior vena cava filter placement prior to surgery. Incomplete key clinical or financial data.

Primary outcome measure(s)

  • Adjusted Odds Ratio (OR) of Symptomatic VTE — Up to 30 days postoperatively.

Trial sites (1)

FacilityCityRegionStatus
Affiliated Hospital of Nantong University Nantong China

More Affiliated Hospital of Nantong University trials in China

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy Recruiting
Autologous Bone Marrow Mesenchymal Stem Cell Therapy for Ischemic Stroke Starting soon
Study of Sivelestat Sodium in OPCABG Recruiting
Wearable Devices Empowering Active Health Initiatives for High-Risk Stroke Populations Recruiting
TS Triage of HR-HPV Positive Population and Its Accuracy Study Active, not recruiting

Other trials for the same condition

Ultrasound Assessment of Isolated Distal Deep Vein Thrombosis Active, not recruiting
Predicting Hypothermia in Gynecological Laparoscopic Surgery Using Machine Learning Starting soon
Acostream Use in Patients With High Risk and Intermediate-risk Acute Pulmonary Embolism Recruiting
Smart Technology Facilitated Patient-centered Venous Thromboembolism Management Starting soon
Smart Technology Facilitated Patient-centered Venous Thromboembolism Management Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07455253 on ClinicalTrials.gov ↗ ← All trials in China